Pacira BioSciences, Inc. (PCRX)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Pacira BioSciences, Inc. (PCRX) is down 14.0% since the beginning of the year. At $22 per share, PCRX is trading 19.5% below its 52-week high of $28. Investors who bought $1,000 worth of PCRX shares 5 years ago would now be looking at an investment worth $358.

Pacira BioSciences, Inc. (PCRX) has returned -14.03% so far this year and -15.72% over the past 12 months. Over the last ten years, PCRX has returned -7.22% per year, falling short of the S&P 500 Index benchmark, which averaged 13.75% annually.

Based on dividend-adjusted daily data since Feb 3, 2011, PCRX's average daily return is +0.08%, while the average monthly return is +1.61%. At this rate, an investment would double in approximately 3.6 years.

Historically, 51% of months were positive and 49% were negative. The best month was Jun 2012 with a return of +51.0%, while the worst month was Sep 2015 at -28.6%. The longest winning streak lasted 8 consecutive months, and the longest losing streak was 5 months.

On a daily basis, PCRX closed higher 51% of trading days. The best single day was Oct 27, 2015 with a return of +19.4%, while the worst single day was Aug 9, 2024 at -47.7%.

Pacira BioSciences, Inc. has an annualized alpha of 8.98%, beta of 0.89, and R2 of 0.10 versus S&P 500 Index. Calculated based on daily prices since February 04, 2011.

• This stock participated in 106.59% of S&P 500 Index downside but only 87.05% of its upside - more exposed to losses than it benefited from rallies.
• R2 of 0.10 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

PCRX ranks 22 for risk / return — below 22% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.

The table below present risk-adjusted performance metrics for Pacira BioSciences, Inc. (PCRX) and compare them to S&P 500 Index.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Pacira BioSciences, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Pacira BioSciences, Inc. was 90.19%, occurring on Aug 9, 2024. The portfolio has not yet recovered.

The current Pacira BioSciences, Inc. drawdown is 81.34%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Pacira BioSciences, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Pacira BioSciences, Inc. is priced in the market compared to other companies in the Drug Manufacturers - Specialty & Generic industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.